Vertex has initial success in new diabetes project

Remarkably positive insulin results have arrived from Vertex's first patient in the phase I/II trial of its stem cell therapy against type 1 diabetes.
Photo: Brian Snyder/Reuters/Ritzau Scanpix
Photo: Brian Snyder/Reuters/Ritzau Scanpix
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN

The results from the first patient to receive Vertex's treatment for type 1 diabetes, VX-880, a therapy derived from stem cells, have been a cause for celebration for the Boston-based biotech company, it reports in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading